Glioblastoma
-
Qiagen and Pfizer to Develop Diagnostic for Brain Tumor Vaccine
Pfizer and DxS (a wholly owned subsidiary of Qiagen) have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110) – an immunotherapy vaccine in development for the treatment of Glioblastoma Multiforme (GBM). F…
Glioblastoma | 18 February 2010
